Indometacin Laropharm (Indometacin)

Indometacin blocks the activity of cyclooxygenase enzymes (COX‑1 and COX‑2), which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, it diminishes inflammation, pain, and fever at the affected sites.

The appropriate dose of Indometacin Laropharm is determined by the prescribing healthcare professional based on the specific condition, severity, patient age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions exactly.

The safety of indometacin in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indometacin is a potent NSAID with strong anti‑inflammatory activity, often considered more effective for certain acute gout attacks compared with some other NSAIDs. However, it may have a higher risk of gastrointestinal and renal side effects, so clinicians balance efficacy against safety when choosing an NSAID.

Store at room temperature: keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Indometacin Laropharm is taken orally, usually with a full glass of water. It may be taken with food or milk to lessen stomach irritation, but patients should follow the specific instructions provided by their prescriber.

Serious risks include gastrointestinal ulceration or bleeding, acute kidney injury, severe liver dysfunction, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and increased risk of cardiovascular events. Patients should be monitored closely for any of these complications.

Indometacin should be avoided in individuals with known hypersensitivity to indometacin or other NSAIDs, active gastrointestinal ulcer disease, severe renal or hepatic impairment, and in patients taking certain anticoagulants or other NSAIDs without medical supervision.